Skip to main content

FERRIPROX®

(deferiprone)

FERRIPROX tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease, or other anemias.

Limitations of use:

  • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Jump to:

FAQs, Other Medical Information, Publications

Frequently Asked Questions

Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman.  Pregnancy testing is recommended for females of reproductive potential prior to initiating Ferriprox.

Contraception
Females
Advise female patients of reproductive potential to use effective contraception during treatment with FERRIPROX and for at least 6 months after the last dose.

Males
Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with FERRIPROX and for at least 3 months after the last dose.

Allow at least a 4-hour interval between Ferriprox and mineral supplements, and antacids that contain polyvalent cations (e.g., iron, aluminum, and zinc).


Publications

Results (- -)

Filter by keyword

Results (- -)

Filter by keyword